Xuefeng Z. Fang

Key Laboratory Of Cancer Prevention And Intervention
Hangzhou, 310009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

ROS-Responsive Hydrogel for Localized Delivery of Nampt and Stat3 Inhibitors Exhibits Synergistic Antitumor Effects in Colorectal Cancer Through Ferroptosis Induction and Immune Microenvironment Remodeling.

ROS-Responsive Hydrogel for Localized Delivery of Nampt and Stat3 Inhibitors Exhibits Synergistic Antitumor Effects in Colorectal Cancer Through Ferroptosis Induction and Immune Microenvironment Remodeling.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 11, 2025

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: March 27, 2025

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.

Journal: The Lancet. Respiratory medicine

Published: February 19, 2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: September 29, 2024

Loss-of-function mutation of REV1 (p.R704Q) mediates cetuximab primary resistance by activating autophagy in RAS-wild type metastatic colorectal cancer.

Loss-of-function mutation of REV1 (p.R704Q) mediates cetuximab primary resistance by activating autophagy in RAS-wild type metastatic colorectal cancer.

Journal: Cancer letters

Published: January 11, 2024

Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial.

Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial.

Journal: EClinicalMedicine

Published: October 16, 2023

Expression and prognostic impact of NTF3 and TrkC in hepatocellular carcinoma.

Expression and prognostic impact of NTF3 and TrkC in hepatocellular carcinoma.

Journal: Scandinavian journal of gastroenterology

Published: June 05, 2023

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.

Journal: EClinicalMedicine

Published: April 11, 2023

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.

Journal: BMC cancer

Published: March 07, 2023

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

Journal: Clinical Medicine Insights. Oncology

Published: February 05, 2023

REV1: A novel biomarker and potential therapeutic target for various cancers.

REV1: A novel biomarker and potential therapeutic target for various cancers.

Journal: Frontiers in genetics

Published: July 19, 2022

Development and validation of a novel prognostic nomogram including tumor deposits could better predict survival for colorectal cancer: a population-based study.

Development and validation of a novel prognostic nomogram including tumor deposits could better predict survival for colorectal cancer: a population-based study.

Journal: Annals of translational medicine

Published: May 14, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026